A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a phase I, multicenter, open label, sequential-cohort, dose escalation study of
ESG206. The purpose is to evaluate the clinical safety, tolerability, PK, and preliminary
efficacy and to establish the MTD, if any, and RP2D(s) of ESG206 in adult subjects with B
lymphoid malignancies.